Provider Briefing: Cyltezo Access in 2026

Cyltezo (Adalimumab-adbm) was a milestone product — the first adalimumab biosimilar to receive FDA interchangeable designation. For rheumatologists, gastroenterologists, and dermatologists, it represented a lower-cost alternative to Humira with the added benefit of pharmacy-level substitution. But in practice, getting patients their Cyltezo prescriptions filled has become increasingly complicated.

This briefing covers what's driving the access challenges, how the competitive landscape has shifted, and what prescribers can do to help patients stay on therapy.

Timeline: Cyltezo's Journey to Market

• August 2017: FDA approves Cyltezo as a biosimilar to Humira.
• October 2021: FDA grants Cyltezo interchangeable designation — the first for any adalimumab biosimilar.
• July 2023: Cyltezo launches commercially in the U.S. after patent litigation settlement with AbbVie. Eight other adalimumab biosimilars also launch in 2023.
• May 2024: FDA approves high-concentration Cyltezo (40 mg/0.4 mL), expanding formulation options.
• 2025: Several PBMs, including Optum Rx, shift preferred formulary status away from Cyltezo to competing biosimilars like Amjevita. Multiple biosimilars achieve interchangeable status.
• Early 2026: No FDA-reported shortage, but pharmacy-level availability remains inconsistent.

Prescribing Implications

Interchangeability Is an Advantage — in Theory

Cyltezo's interchangeable status means pharmacists can substitute it for Humira without prescriber intervention (subject to state laws). In practice, this has had limited impact because the decision of which adalimumab product a pharmacy stocks is driven by PBM contracts, not interchangeability status. As of 2025, Amjevita and Hyrimoz have also achieved interchangeable designation, diluting Cyltezo's earlier competitive advantage.

Prior Authorization Remains Common

Regardless of which adalimumab product you prescribe, most insurance plans require prior authorization. The PA process typically involves documenting:

• Confirmed diagnosis of an FDA-approved indication
• Failure or intolerance of conventional therapies (e.g., methotrexate for RA, aminosalicylates for IBD)
• TB screening results
• Hepatitis B screening

Some plans have implemented step therapy protocols requiring a trial of their preferred biosimilar before covering Cyltezo. When switching patients, be prepared for potential PA denials and have an appeals strategy.

Formulary Awareness Is Critical

Prescribers should be aware of which adalimumab products are preferred by their patients' insurance plans. In 2025–2026, the landscape has shifted significantly:

• Optum Rx: Dropped Cyltezo; prefers Amjevita
• Express Scripts: Varies by plan, but Hyrimoz and Amjevita have gained preferred status
• CVS Caremark: Plan-dependent; some formularies include Cyltezo
• Medicare Part D: Coverage varies widely; prior authorization is nearly universal

Prescribing a non-preferred product leads to delays, increased patient out-of-pocket costs, and potentially missed doses.

The Availability Picture

There is no national manufacturing shortage of Cyltezo. Boehringer Ingelheim continues to produce the medication. However, pharmacy-level stocking is driven by demand, which is in turn driven by formulary placement.

The practical result:

• Large chain pharmacies may not stock Cyltezo if it's not preferred by their most common PBM contracts.
• Specialty pharmacies remain the most reliable source for Cyltezo and other adalimumab biosimilars.
• Independent pharmacies may special-order Cyltezo with 1–2 business days lead time.

Providers can help patients by directing them to specialty pharmacy channels early in the prescribing process rather than sending prescriptions to retail pharmacies.

Cost and Access Considerations

Cyltezo's wholesale acquisition cost positions it competitively among adalimumab biosimilars, but the patient's out-of-pocket cost depends heavily on insurance coverage:

• Cash price: ~$7,500–$7,900/month
• With commercial insurance + copay card: Often $0/month through Boehringer Ingelheim's Savings Copay Program
• With discount cards (uninsured): ~$1,200–$1,300/month
• Medicare patients: Coverage varies; copay cards are not available for government-funded insurance

For uninsured or underinsured patients, Boehringer Ingelheim's Patient Assistance Program through the BI Cares Foundation may provide Cyltezo at no cost. NeedyMeds (needymeds.org) and RxAssist (rxassist.org) are additional resources. See our patient-facing guide: How to Save Money on Cyltezo.

For detailed provider-specific savings information, see our provider's guide to helping patients save on Cyltezo.

Tools and Resources for Providers

• Medfinder for Providers: Check real-time pharmacy availability for Cyltezo and other medications. Direct patients to pharmacies with confirmed stock.
• Boehringer Ingelheim Professional Resources: pro.boehringer-ingelheim.com/us/products/cyltezo — prescribing information, copay support details, and patient education materials.
• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — verify current shortage status.
• Specialty Pharmacy Networks: Many health systems have preferred specialty pharmacy relationships. Utilize these for smoother fulfillment of biologic prescriptions.

Looking Ahead

The adalimumab biosimilar market is still maturing. Over time, market consolidation may reduce the number of actively competing products, potentially improving availability for those that remain. However, in the near term, prescribers should expect continued formulary volatility and plan-level variation in which products are easiest for patients to access.

Key trends to watch in 2026:

• Additional interchangeable designations for other biosimilars
• PBM formulary decisions for the 2027 plan year
• Potential market exits by less competitive biosimilar manufacturers
• Growth of unbranded biologic products (e.g., unbranded adalimumab-adbm)

Final Thoughts

The challenge with Cyltezo isn't supply — it's access. Formulary preferences, PBM negotiations, and pharmacy stocking patterns create a fragmented landscape that can leave patients without their medication.

As prescribers, the most impactful steps you can take are: know your patients' formularies, utilize specialty pharmacy channels, and leverage tools like Medfinder to help patients locate available stock. When Cyltezo isn't accessible, therapeutic alternatives are readily available, and switching between adalimumab products is clinically straightforward.

Keeping patients on therapy should always be the priority.